NCT05328167CompletedPhase 2
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Contrast-Enhanced Ultrasound for Diagnosis and Therapy of Cholangiocarcinoma
Source: ClinicalTrials.gov · Last updated 28 Oct 2025
Brief summary (registry, in English)
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment). Contrast-enhanced ultrasound uses gas microbubbles that may provide enhancement on ultrasound. It is also possible to pop these microbubbles using ultrasound imaging. Tumors that experience popping of these microbubbles may be easier to kill with radiotherapies. Therefore, this trial may also help doctors see if ultrasound-triggered microbubble popping can improve bile duct cancer response to radiotherapy. Another purpose of this trial is to test if the pressure inside the tumor estimated through ultrasound can be used to predict the tumor response to radiotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 7 Apr 2022
- Start date
- 14 Dec 2021
- Primary completion date
- 31 Jul 2025
- Lead sponsor
- Thomas Jefferson University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05328167
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 16
- From 14 Dec 2021 to the primary completion date, 31 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with recent cerebral hemorrhage
- Patients with known hypersensitivity to perflutren
- Patients with known congenital heart defects
- Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli
Lab values
- Patients with known sensitivities to albumin, blood, or blood products
- Patients with bilirubin levels \> 2 mg/dL
Other
- Females who are pregnant or nursing
Who the study is looking for
- Be scheduled for sub-lobar radioembolization therapy of a previously untreated intrahepatic cholangiocarcinoma greater than 1 cm but small enough to be fully visualized in the ultrasound three-dimensional (3D) volume (approximately 6 cm maximum diameter, but depth dependent)
- Be at least 18 years of age
- Be medically stable
- If a female of child-bearing age, have a negative pregnancy test prior to each ultrasound exam
- Have signed Informed Consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sidney Kimmel Cancer Center at Thomas Jefferson University Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.